Clinical trials
Pulmonary Fibrosis clinical trials
Below are recruiting pulmonary fibrosis clinical trials, each written for real people, not researchers. We’re tracking 138 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07652658RecruitingPhase 2
Study of AZD8965 for people with IPF
This trial tests a new drug called AZD8965 for Idiopathic Pulmonary Fibrosis (IPF). It aims to see if the drug can help people with IPF either on current treatments or not on standard therapy.
Birmingham, AlabamaAges 40 years+ - NCT07482917Recruiting
Streamlining the diagnosis of interstitial lung disease
This study is testing a new way to speed up the diagnosis of interstitial lung disease (a group of lung scarring conditions). If you have symptoms or scan findings that suggest ILD but haven't been fully diagnosed yet, this trial may help you get a faster, clearer answer.
Granollers, BarcelonaAges 18 years+ - NCT07464132RecruitingPhase 1/Phase 2
New PET scan for detecting certain diseases
This trial uses a special PET scan tracer to see if it can help find and monitor diseases linked to a protein called FAP. It is for both cancer patients needing a biopsy and healthy volunteers.
Beijing, Beijing MunicipalityAges 18–85 - NCT07454291RecruitingPhase 1
How taladegib works in healthy volunteers
This trial is for healthy volunteers to see how the study drug taladegib (ENV-101) interacts with other medicines in the body. It will help researchers understand how the drug is absorbed and processed, which is important for future studies in patients.
Brisbane, QueenslandAges 26–65 - NCT06815185Recruiting
Counseling help for people with interstitial lung disease
This study tests a counseling program to help people with interstitial lung disease (a group of lung conditions that cause scarring and make breathing harder) with rehabilitation and support. It may help you cope better and stay active.
Bologna, BolognaAges 18 years+ - NCT07407543RecruitingPhase 1
Study of SRN001 in healthy Korean and Caucasian men
This trial tests a new drug called SRN001 in healthy men to see how safe it is and how the body processes it. It may help find the right dose for future studies.
SeoulAges 19–60 - NCT05016817RecruitingPhase 1
Testing an IV stem cell treatment for idiopathic pulmonary fibrosis
This Phase 1 study tests whether an IV infusion of stem cells from donated umbilical cord tissue is safe for people with idiopathic pulmonary fibrosis. It focuses mainly on safety and tolerability, and it may help by offering a new treatment approach if the cells are safe for you.
St John'sAges Any age - NCT07192939RecruitingPhase 2
Testing HRS-9813 for progressive pulmonary fibrosis
This trial tests a new drug called HRS-9813 for people with pulmonary fibrosis (scarring in the lungs) that continues to worsen. It looks at whether the drug can slow down the disease compared to a placebo.
Beijing, Beijing MunicipalityAges 21 years+ - NCT07174102Recruiting
Looking at lung scans in rheumatoid arthritis and related diseases
This trial studies lung scans (HRCT) from patients with rheumatoid arthritis, interstitial lung disease, or connective tissue disease to better understand lung involvement. If you have one of these conditions and have had a lung CT, you may be able to help.
PragueAges 18 years+ - NCT07082842RecruitingPhase 3
Testing HEC585 tablets for idiopathic pulmonary fibrosis
This trial tests a new tablet, HEC585, for people with idiopathic pulmonary fibrosis (IPF). It aims to see if the drug can help improve lung function and slow the disease. Participants must have a confirmed IPF diagnosis and meet specific breathing test results.
Beijing, Beijing MunicipalityAges 40–80 - NCT07019714Recruiting
A movement therapy to improve walking ability in IPF
This trial tests a gentle exercise technique (Daoyin) to help people with Idiopathic Pulmonary Fibrosis (IPF) feel less short of breath and walk farther. It is done at home with a smartphone or computer.
Beijing, Beijing MunicipalityAges 40–85 - NCT06885515Enrolling by invitation
Telomere length in Israeli patients with fibrotic ILD
This study looks at the length of telomeres (a part of your DNA) in people with fibrotic interstitial lung disease (ILD) in Israel. It aims to understand how telomere length relates to this condition and may help guide future care.
AshkelonAges 18 years+ - NCT06817590RecruitingPhase 1
Nucleoside therapy for telomere disorders
This trial tests a nucleoside therapy (dC/dT) for people with telomere biology disorders, which cause premature aging and problems like low blood counts, lung or liver issues. The goal is to see if the treatment can help manage these symptoms.
Boston, MassachusettsAges 1–70 - NCT06325696RecruitingPhase 2
H01 for adults with lung scarring (SOLIS study)
This study tests an oral medication (H01/hymecromone) to see if it can help people with progressive lung scarring (ILD). It lasts about 12 to 24 weeks and requires good lung function without needing oxygen at rest.
Research Triangle Park, North CarolinaAges 18–100 - NCT06267183RecruitingEarly Phase 1
Safety study of a new drug in healthy volunteers
This study tests a new investigational drug called SV001 in healthy volunteers to see if it is safe and how the body handles it. It is a first-in-human trial, meaning this drug has not been tested in people before.
ShanghaiAges 18–45 - NCT05988463RecruitingPhase 1
Study of artesunate for people with idiopathic pulmonary fibrosis
This study tests artesunate, a medicine that may help treat idiopathic pulmonary fibrosis (IPF), a condition that causes lung scarring. It is for people who are already taking other IPF treatments and want to see if adding artesunate can improve their condition.
Stanford, CaliforniaAges 40 years+ - NCT05190211Recruiting
Video exercise therapy for idiopathic pulmonary fibrosis
This study tests whether telerehabilitation (supervised exercise/therapy by video or remote tools) can help people with idiopathic pulmonary fibrosis (IPF) improve breathing and function. You may be able to take part if your condition has been stable and you haven’t recently done a pulmonary rehab program.
Istanbul, ZeytinburnuAges 18–75 - NCT05903001Recruiting
Breathing muscle testing to help track lung disease
This study checks whether measurements of your breathing muscle (the diaphragm) can act as a useful “biomarker” to track lung disease. You might be asked to do breathing tests and follow study instructions, and your results may help researchers better monitor COPD, asthma, fibrosis, or pulmonary hypertension.
Aachen, North Rhine-WestphaliaAges 18 years+ - NCT05139719RecruitingPhase 2
HEC585 trial for slowing lung scarring decline
This Phase 2 study tests whether HEC585 can slow the decline in lung function in people with progressive fibrosing interstitial lung disease (PF-ILD). It may help preserve breathing capacity and breathing tolerance over time.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04896138Enrolling by invitation
Natural history study for lung scarring patients
This study follows people who are being seen for lung scarring (also called ILD) and compares them with family members without lung scarring. It helps researchers better understand how this condition changes over time and what to look for in the future.
Charlottesville, VirginiaAges 18 years+ - NCT03500731RecruitingPhase 1/Phase 2
Lung and bone marrow transplant for lung and blood failure
This Phase 1/2 study tests a special lung-and-bone-marrow transplant approach for people with severe lung disease and bone marrow failure (low blood counts). The goal is to see if the treatment is safe and whether it can improve outcomes when standard long-term immune-suppressing medicines are a poor fit.
Pittsburgh, PennsylvaniaAges 18–60 - NCT03800017Recruiting
Muscle strength and exercise function in lung scarring
This study looks at how well skeletal (muscle) function supports exercise in people with interstitial lung diseases (including idiopathic pulmonary fibrosis). It may help better understand fitness and breathing limits, which can guide rehabilitation choices and future care.
Vancouver, British ColumbiaAges 40–80 - NCT00470327Recruiting
Study of how interstitial lung disease naturally changes
This study looks at how interstitial lung disease (lung scarring) typically progresses over time. It may help researchers understand what to expect and what changes to watch for.
Chicago, IllinoisAges 18 years+ - NCT06940427RecruitingPhase 2
Testing a new PET scan for lung scarring
This trial is testing a new type of PET scan (FAPI PET) to help doctors see if lung scarring (fibrosis) is getting worse or getting better. It may help decide if a treatment change is needed.
Madison, WisconsinAges 18 years+
Hear when a new Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pulmonary fibrosis?
- Yes. Clin2 currently lists 138 recruiting pulmonary fibrosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pulmonary fibrosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pulmonary fibrosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.